波士顿科学第二季度介入心脏病学与神经调节业务增长强劲

环球市场播报07-30

医疗科技公司波士顿科学公布了2026年第二季度财报。尽管Watchman心脏植入装置业务放缓和电生理业务竞争加剧导致公司下调了全年展望，但季度业绩仍凭借介入心脏病学和神经调节等业务的强劲表现超出市场预期。　　财报显示，公司第二季度净销售额为54.42亿美元，同比增长7.5%，超过市场预期的53.6亿美元。调整后每股收益为86美分，同比增长15%，高于公司此前82至84美分的指引区间和市场预期的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2655314815?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-30 03:47","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2655314815","market":"other","top_or_hot":-1,"title":"波士顿科学第二季度介入心脏病学与神经调节业务增长强劲","media":"环球市场播报","content":"<div>\n<p>医疗科技公司波士顿科学公布了2026年第二季度财报。尽管Watchman心脏植入装置业务放缓和电生理业务竞争加剧导致公司下调了全年展望，但季度业绩仍凭借介入心脏病学和神经调节等业务的强劲表现超出市场预期。\n　　财报显示，公司第二季度净销售额为54.42亿美元，同比增长7.5%，超过市场预期的53.6亿美元。调整后每股收益为86美分，同比增长15%，高于公司此前82至84美分的指引区间和市场预期的...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-07-30/doc-inikphnx5473604.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>波士顿科学第二季度介入心脏病学与神经调节业务增长强劲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n波士顿科学第二季度介入心脏病学与神经调节业务增长强劲\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-30 03:47 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-07-30/doc-inikphnx5473604.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>医疗科技公司波士顿科学公布了2026年第二季度财报。尽管Watchman心脏植入装置业务放缓和电生理业务竞争加剧导致公司下调了全年展望，但季度业绩仍凭借介入心脏病学和神经调节等业务的强劲表现超出市场预期。\n　　财报显示，公司第二季度净销售额为54.42亿美元，同比增长7.5%，超过市场预期的53.6亿美元。调整后每股收益为86美分，同比增长15%，高于公司此前82至84美分的指引区间和市场预期的...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-07-30/doc-inikphnx5473604.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0011850046.USD","symbol_name":"贝莱德全球长线股票 A2 USD","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-30/doc-inikphnx5473604.shtml","article_id":"2655314815","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655314815","pubTimestamp":1785354420,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"医疗科技公司波士顿科学公布了2026年第二季度财报。尽管Watchman心脏植入装置业务放缓和电生理业务竞争加剧导致公司下调了全年展望，但季度业绩仍凭借介入心脏病学和神经调节等业务的强劲表现超出市场预期。神经调节业务销售额增长12.7%，疼痛和脑部治疗领域均实现两位数增长，受益于对Nalu的整合。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4504":"桥水持仓","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0138981039.USD":"FIDELITY FUNDS SUSTAINABLE MULTI ASSET INCOME \"A\" INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","SG9999001176.USD":"United Global Healthcare Acc USD","BSX":"波士顿科学","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4581":"高盛持仓","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"translate_title":"Boston Scientific's Interventional Cardiology & Neuromodulation Business Grows Strong in Q2","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1.5},"content_text":"医疗科技公司波士顿科学公布了2026年第二季度财报。尽管Watchman心脏植入装置业务放缓和电生理业务竞争加剧导致公司下调了全年展望，但季度业绩仍凭借介入心脏病学和神经调节等业务的强劲表现超出市场预期。\n　　财报显示，公司第二季度净销售额为54.42亿美元，同比增长7.5%，超过市场预期的53.6亿美元。调整后每股收益为86美分，同比增长15%，高于公司此前82至84美分的指引区间和市场预期的83美分。\n　　各业务板块中，心血管业务净销售额为36.24亿美元，同比增长8.3%，其中介入心脏病学与血管疗法业务增长最为突出，有机增长率达12.1%，冠状动脉疗法业务实现两位数增长，AGENT药物涂层球囊表现尤其强劲。神经调节业务销售额增长12.7%，疼痛和脑部治疗领域均实现两位数增长，受益于对Nalu的整合。内窥镜业务增长7%，而泌尿业务仅增长0.8%，表现低于预期。\n　　从区域看，美国市场销售额增长6.2%，亚太地区增长11.2%，拉美和加拿大地区增长22.4%。调整后营业利润率为28.4%，同比提升约70个基点。\n　　不过，公司因Watchman业务放缓和电生理市场竞争超出预期而下调了全年业绩指引。全年有机销售增长预期从此前的6.5%至8%下调至5%至6%，全年调整后每股收益预期从3.34至3.41美元下调至3.28至3.32美元。公司表示这些不利因素可能延续至2027年，预计2028年增长将明显改善。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655314815","isCrawlerRequest":true}